Celltrion announced on Sept. 4 that it recently obtained sales approval for its Avastin (bevacizumab) biosimilar Vegzelma from the Australian Therapeutic Goods Administration (TGA).
Celltrion has been granted sales approval for Vegzelma in Australia for the entire range of indications approved for Avastin, including metastatic colorectal cancer, non-small cell lung cancer, metastatic renal cell carcinoma, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and glioblastoma.
With this approval, the number of commercialized products by Celltrion in Oceania is expected to increase to six, potentially bolstering the company's influence and competitiveness on the continent. Notably, Australia is a leading country that encourages biosimilar prescriptions and is actively pushing for policy support in favor of biosimilars.
Since 2015 in Australia, starting with the autoimmune disease treatment Remsima, Celltrion has gained approval for a total of six products. These include blood cancer treatment Truxima, breast cancer and gastric cancer treatment Herzuma, autoimmune disease treatments Remsima SC and Yuflyma, and now, the metastatic colorectal cancer treatment Vegzelma. This has steadily expanded Celltrion's foothold in the market.